PHLPP belongs to a novel family of protein phosphatases that serve as negative regulators of Akt. There are two isoforms, PHLPP1 and PHLPP2, identified in this family. Our previous studies have indicated a tumor suppressor role of both PHLPP isoforms in colon cancer. Here, we report that the expression of PHLPP is controlled by mTOR-dependent protein translation in colon and breast cancer cells. Treating cells with rapamycin or knockdown of mTOR using RNAi results in a marked decrease of PHLPP protein expression. In contrast, stable knockdown of TSC2, a negative regulator of mTOR activity, increases PHLPP expression.
The rapamycin-mediated downregulation of PHLPP is blocked by expression of a rapamycin-insensitive mutant of p70S6K. In addition, depletion of 4E-BP1 expression by RNAi results in an increase of PHLPP expression and resistance to rapamycin-induced downregulation. Moreover, inhibition of mTOR activity by amino acid or glucose starvation reduces PHLPP expression in cells. Functionally, we show that rapamycinmediated inhibition of PHLPP expression contributes to rapamycin resistance in colon cancer cells. Thus, our studies identify a compensatory feedback regulation in which the activation of Akt is inhibited by upregulation of PHLPP through mTOR, and this mTORdependent expression of PHLPP subsequently determines the rapamycin sensitivity of cancer cells.
Activation of Akt signaling pathways downstream of mitogen receptors and phosphoinositide 3-kinase (PI3K) plays pivotal roles in controlling cell growth, proliferation, and apoptosis (1) . Dysregulation of PI3K/Akt signaling is commonly associated with human diseases such as cancer and diabetes (2) (3) (4) . Akt belongs to the AGC kinase superfamily. Like most of the kinases in this family, the activation of Akt requires phosphorylation at two critical sites: the activation loop (Thr308) site within the kinase core phosphorylated by PDK-1 and the hydrophobic motif (Ser473) site in the C-terminus phosphorylated by the TORC2 complex (1) . By serving as a master kinase for a growing numbers of substrates, Akt exerts its influence over many critical cellular processes such as cell cycle, cell survival, and metabolism. However, it has been suggested that the oncogenic activity of Akt is largely attributed to its ability to activate the mTOR pathway (5) .
mTOR is an evolutionarily conserved protein kinase that forms two distinct complexes in cells: mTORC1 (mTOR complex 1), also termed the rapamycin-sensitive complex, is responsible for controlling cell size by regulating protein translation; and mTORC2 (mTOR complex 2), the rapamycin-resistant complex, serves as the upstream activator of Akt (6) . In response to growth factor stimulation, mTORC1-dependent protein translation is activated following Akt mediated-phosphorylation of TSC2, which releases its negative regulation of Rheb and subsequently activates mTORC1. The accelerated protein translation is controlled by mTORmediated phosphorylation of its substrates, p70S6 kinase (p70S6K) and 4E-BP1 (7, 8) . Specifically, activation of p70S6K by mTOR leads to increased phosphorylation and recruitment of eIF4B to the translation pre-initiation complex, which enhances the RNA helicase activity of eIF4A in the complex and facilitates mRNA translation (9) . In addition, mTOR-mediated phosphorylation dissociates the negative regulator 4E-BP1 from the 5'-cap binding protein eukaryotic translation initiation factor 4E (eIF4E), thus releasing its inhibition on capdependent translation (9) . In addition, mTOR pathway is regulated by nutrient availability. Under amino acid-rich condition, mTORC1 is activated via a Rag GTPase-dependent mechanism to promote protein synthesis (10) . Amino acid deprivation effectively turns off mTORC1 activity as shown by decreased phosphorylation of p70S6K and 4E-BP1 leading to dramatic reduction of protein translation (10, 11) .
Since the activity of Akt is tightly controlled by phosphorylation, direct dephosphorylation of Akt mediated by protein phosphatases results in effective inactivation of the kinase. Recently, we have identified a novel family of Ser/Thr protein phosphatases, PHLPP, that dephosphorylate Akt and attenuate Akt signaling (12, 13) . Two isoforms of PHLPP, namely PHLPP1 and PHLPP2, sharing ~50% identity at the amino acid level are found in this phosphatase family. Our previous studies have demonstrated that PHLPP functions as a tumor suppressor in human colorectal cancers as downregulation of both PHLPP isoforms occurs at high frequency in patient specimens (14) . In addition, overexpression of either PHLPP isoform in colon cancer cells leads to decreased cell proliferation and increased sensitivity to PI3K inhibitor-induced growth arrest (14) . Furthermore, it has been shown recently that Akt is negatively regulated by FKBP51, a scaffolding protein for Akt and PHLPP. This FKBP51 dependent-and PHLPP mediated-dephosphorylation of Akt dictates the response of cancer cells to chemotherapeutic drugs (15) .
In this study, we report the identification of PHLPP as a translational target of mTORC1. We show that the protein expression of both PHLPP isoforms is regulated by mTOR activity. In addition, we examine the hypothesis that rapamycin-induced downregulation of PHLPP expression contributes to rapamycin resistance in cancer cells.
EXPERIMENTAL PROCEDURES
Reagents -The expression plasmid for HA-tagged p70S6K-T389E was generously provided by Dr. John Blenis (Harvard Medical School). Amino acid-free MEM was purchased from US Biological. The following antibodies were purchased from commercial sources: polyclonal antibodies for PHLPP1 and PHLPP2 from Bethyl Laboratory; polyclonal antibodies against Akt, 4E-BP1, p70S6K, TSC2, mTOR, S6, phospho-Akt (including T308 and S473), phospho-p70S6K (T389), and phospho-S6 (S240/S244) from Cell Signaling; and anti-γ-Tubulin mAb from Sigma.
Cells -Human colon cancer cell lines SW480 and KM20 were cultured in DMEM and MEM (supplemented with 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 2X-vitamin solution), respectively. 293T and breast cancer MB-MDA231 cells were cultured in DMEM. All media were supplemented with 10% fetal bovine serum (FBS, Hyclone) and penicillin/streptomycin. Transient transfection of all cell types was carried out using Lipofectamine 2000 transfection reagents (Invitrogen). The shRNA for human 4E-BP1 and p70S6K gene was constructed in pLKO.1-puro vector and purchased from Sigma-Aldrich (16) , and the targeting sequences are as the following: 4E-BP1, 5'-GCGCAATAGCCCAGAAGATAA-3'; and p70S6K (stable cells were generated by combining two targeting sequences), 5'-CCGGAGAATATCATGCTTAAT-3' and 5'-GCAATCTGAAGAGGATGTAAG-3'. The shRNAs for human TSC2, mTOR, raptor, and rictor genes in pLKO.1-puro vector were obtained from Addgene, and the specificity of the targeting sequences have been verified and described previously (17, 18) . The lentivirus-mediated delivery of shRNA and selection for stable knockdown cells were carried out as previously described (14) .
Retrovirus-mediated overexpression of PHLPP isoforms -To express PHLPP1 and PHLPP2 in colon cancer KM20 and SW480 cells, the cDNA sequences encoding the HA-tagged PHLPP1 and PHLPP2 were excised from the pcDNA4-TO-PHLPP1 and pcDNA4-TO-PHLPP2 expression constructs (14) using PmeI, and subsequently subcloned into the SnaBI site on the pBabe-puro vector (Addgene). The retrovirus was produced by transfecting 293T cells with pBabe-puro-PHLPP1 or pBabe-puro-PHLPP2 together with pCLAmpho packaging plasmid. The cell culture supernatants collected from the transfected cells were used directly in infecting colon cancer cells. For generating stable cells, the infected cells were pooled and selected against puromycin.
Rapamycin and Torin1 mediated downregulation of PHLPP proteins -Equal numbers of cells from different cell lines were seeded onto 12-well plates and allowed to reach ~70% confluency. The cells were treated with rapamycin (20 nM) or Torin1 (100 nM) and harvested at indicated time points. The cells were lysed in Lysis Buffer (50 mM Na 2 HPO 4 , 1 mM sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton X-100, 1 mM DTT, 200 µM benzamidine, 40 µg ml -1 leupeptin, 200 µM PMSF) and the detergentsolublized cell lysates were subjected to Western blot analysis. The density of Western blot signals was obtained and quantified using a FluoChem digital imaging system (Alpha Innotech).
Amino acid starvation and stimulation of cells -
For amino acid starvation, cells grown in regular growth medium were rinsed with and incubated in amino acid-free and serum-free MEM (supplemented with 584 µg/ml L-glutamine) for 50 minutes. Subsequently, the cells were stimulated by switching to regular serum-free DMEM containing normal concentration of amino acids for 1 hour. The cell lysates were prepared in Lysis Buffer and analyzed as described above.
Cycloheximide (CHX) chase assay -Equal numbers of control and TSC2 knockdown 293T cells were seeded onto 12-well plates and allow to attach for ~18 hours. The cells were treated with CHX (20 mg/ml) and harvested at indicated time points. The cell lysates were prepared in SDS sample buffer directly, and the equal amount of lysates were analyzed by Western blotting. To examine the effect of rapamycin, one set of 293T cells were pretreated with rapamycin (20 nM) for 30 minutes prior to the addition of CHX.
Cell proliferation assay -To determine the rate of proliferation, equal numbers of cells were seeded into 12-well plates (2 × 10 4 cells/well) and allowed to grow for an additional 72 hours. Different concentrations of rapamycin were added to the cell culture media at time 0. At the end of the experiments, the cells were fixed and stained with 0.5% crystal violet in 20% methanol for 30 minutes. After washing with water, the stained cells were dissolved in 1% SDS and absorbance at 570 nm was determined (14) . 
Real-time PCR -

RESULTS
PHLPP expression is downregulated by inhibiting mTOR activity -During our experiments to examine the functional interplay between PHLPP and Akt/mTOR pathway, we were intrigued by the observation that the expression of both PHLPP isoforms was downregulated in cells treated with rapamycin. As shown in Fig. 1A , the levels of both PHLPP1 and PHLPP2 proteins were decreased by 50-80% in 293T, MB-MDA231, KM20, and SW480 cells after 8 hours of rapamycin treatment. Note that there are two splicing variants of PHLPP1, PHLPP1α (the short form) and PHLPP1β (the long form) (12) , expressed in some cell lines (such as MB-MDA231, KM20, and SW480 cells). However, since the expression of PHLPP1α is not observed in all cell lines used in our study, the subsequent experiments focus on the predominant endogenous isoform, PHLPP1β. The regulation of PHLPP1α expression is very similar as PHLPP1β in cells where both splicing variants are detected (data not shown). To keep the nomenclature consistent, we simply refer PHLPP1β as PHLPP1 through out the remainder of this study. In addition, since rapamycin has been well documented for its anti-growth effect, we examined whether the cell proliferation was inhibited by rapamycin. The results showed that the cell viability was not significantly altered after the 8-hour rapamycin treatment (data not shown).
To further assess whether alteration of mTOR activity in either mTORC1 or mTORC2 complex affects PHLPP expression, stable knockdown cells were generated using lentivirus-based shRNA targeting mTOR, raptor, and rictor. In both KM20 and SW480 colon cancer cells, knockdown of mTOR expression resulted in ~40-50% reduction in PHLPP1 and PHLPP2 expression ( Fig. 1B and  1C ). Interestingly, knockdown of raptor expression had a similar effect on PHLPP expression in both cell lines, as the levels of both PHLPP isoforms decreased by ~50% ( Fig. 1B and  1C ). In contrast, only a small decrease of PHLPP expression was observed in rictor knockdown cells ( Fig. 1B and 1C ). The phosphorylation of p70S6K at T389 site and its downstream substrate S6 was significantly decreased in mTOR and raptor knockdown cells, whereas the phosphorylation of Akt at S473 site was similarly reduced in mTOR and rictor knockdown cells, thus confirming the effective depletion of mTORC1 and mTORC2 components in these cells (Fig. 1B) . Consistent with previous findings that the phosphorylation of Akt at T308 site is mediated by PDK-1 (19), knockdown of raptor or rictor had little effect on T308 phosphorylation (Fig. 1B) . The small increase of phosphorylation at T308 site observed in mTOR knockdown cells is likely due to the release of feedback inhibition. Collectively, these initial results suggest that the expression of both PHLPP isoforms depends on mTOR activity in cells. Since the disruption of mTORC2 complex had little effect on PHLPP expression as seen in rictor knockdown cells, we postulated that both PHLPP isoforms are translational targets of mTOR in the mTORC1 complex.
Activation of mTOR pathway increases PHLPP expression in cells -
Since mTOR activity is negatively regulated by TSC2 which serves as a GTPase activation protein (GAP) to promote GTP hydrolysis and inactivation of RheB, a small Gprotein activator of mTOR, we examined whether PHLPP expression is controlled by TSC2 in cells. Stable knockdown cells were generated using TSC2 specific shRNA in KM20 and SW480. The expression of TSC2 was decreased by ~70-90% in the stable knockdown cells, while mTOR activity was enhanced as shown by increased phosphorylation of p70S6K and S6 ( Fig. 2A) . The phosphorylation of Akt was decreased in TSC2 knockdown cells as a result of activation of p70S6K-dependent negative feedback loop ( Fig.  2A) . Consequently, the expression levels of both PHLPP isoforms were markedly increased by 50-80% in the TSC2 knockdown cells compared to the control cells in both cell lines (Fig. 2B) . Furthermore, we investigated the PHLPP protein expression in the TSC2 knockout rat embryonic fibroblast (REF) cells (20) . Similar to the TSC2 knockdown cancer cells, the expression of both PHLPP isoforms was elevated in TSC2 knockout REF cells (Fig. 2C ). Taken together, these results show that activation of mTOR upon losing its negative regulator TSC2 leads to increased expression of PHLPP proteins.
PHLPP
expression is regulated by downstream effectors of mTOR -To further understand the mechanism underlying mTORmediated regulation of PHLPP expression, we examined the contribution of two best characterized mTOR effectors, 4E-BP1 and p70S6K, in controlling the levels of PHLPP proteins. To this end, we first determined whether knockdown of p70S6K expression changes PHLPP expression in cells. As shown in Fig. 3 , the expression of both PHLPP isoforms decreased by 40-50% in stable p70S6K knockdown cells. The functional depletion of p70S6K was confirmed by decreased phosphorylation of S6, a downstream substrate of p70S6K (Fig. 3A) . We next examined whether overexpression of a constitutively active mutant p70S6K was able to rescue PHLPP expression from rapamycin-induced downregulation. 293T cells transfected with vector or T389E mutant, a phosphomimetic mutant of p70S6K, were treated with rapamycin for 0-24 hours. Expression of T389E rendered cells partially resistant to rapamycin-induced inactivation of p70S6K pathway, as persistent S6 phosphorylation was observed only in T389E transfected cells (Fig. 3C, lines 7-12) . Consistent with data shown in Fig. 1A , rapamycin treatment resulted in a rapid downregulation of PHLPP expression in vector transfected cells (Fig. 3C,  lanes 1-6) . In marked contrast, both PHLPP isoforms were largely resistant to rapamycin in cells expressing T389E mutant (Fig. 3C, lanes 7-12) . At the end of 24-hour treatment, more than 80% of PHLPP proteins were downregulated in the control cells, while the majority of both PHLPPs remained in T389E transfected cells (Fig.  3D) . Moreover, the basal expression of both PHLPP isoforms was increased by 30-40% in cells expressing T389E mutant (Fig. 3C and 3D) .
Furthermore, we investigated whether PHLPP expression is controlled by 4E-BP1, a negative regulator of cap-dependent translation downstream of mTOR. Stable knockdown cells were generated to deplete endogenous 4E-BP1 expression using lentiviral-based shRNA. In KM20 and MB-MDA-231 cells, knockdown of 4E-BP1 expression resulted in a consistent increase in the levels of both PHLPP isoforms (Fig. 4A and 4B) . Consistent with PHLPP upregulation, the phosphorylation of Akt at S473 site was decreased in the knockdown cells (Fig. 4A ). In addition, we determined the effect of knocking down 4E-BP1 on rapamycin-mediated loss of PHLPP expression. A newly reported mTOR kinase inhibitor, Torin1, was included here in addition to rapamycin to confirm the involvement of mTOR, as a more complete inhibition of mTOR was achieved when using Torin1 (21) . In MB-MDA-231 cells, both rapamycin and Torin1 reduced PHLPP expression by ~50% after 12-hour treatment in control cells. However, knockdown of 4E-BP1 rendered the cells resistance to rapamycin-or Torin1-mediated downregulation of PHLPP levels ( Fig. 4C and  4D) . Similarly, the expression of both PHLPP isoforms was insensitive to Torin1 treatment in 4E-BP1 knockdown KM20 cells (data not shown). Taken together, these results indicate that the two downstream targets of mTOR, p70S6K and 4E-BP1, play an important role in regulating PHLPP expression. While inhibiting mTOR activity by rapamycin or Torin1 significantly reduces PHLPP levels, overexpression of a rapamycin resistant mutant p70S6K or depletion of the negative regulator of protein translation 4E-BP1 rescues PHLPP expression.
The protein stability and the transcriptional control of PHLPP mRNAs are not altered by altering mTOR activity -Since mTOR is a master regulator of protein translation, we hypothesized that the expression of PHLPP is controlled by mTOR via a translational mechanism. Alternatively, it is possible that the stability or mRNA expression of PHLPP proteins is altered by the mTOR signaling pathway. To test this, we performed CHX chase experiments in the control and TSC2 knockdown cells to determine the degradation time course of PHLPP proteins. Although the basal expression of both PHLPP isoforms was increased in TSC2 knockdown cells as described in Fig. 2 , the decay rate of either PHLPP isoform was not changed upon activation of mTOR in TSC2 knockdown cells (Fig. 5A and 5B). The half-life of PHLPP1 and PHLPP2 was approximately 4 and 8 hours, respectively, in both control and TSC2 knockdown cells (Fig. 5B) . In addition, we determined the time course of PHLPP degradation in the presence or absence of rapamycin. As shown in Fig. 5C , rapamycin treatment did not change the time course of PHLPP degradation. Compared to the control cells, the half-life of either PHLPP isoform remained the same in cells treated with rapamycin (Fig. 5D) . Furthermore, we examined the levels of mRNA expression in cells with altered mTOR activity using real-time PCR. Treating cells with rapamycin had no effect on the mRNA levels of PHLPP (Fig. S1) . Similarly, no significant difference in PHLPP mRNA expression was detected in p70S6K and mTOR knockdown cells compared to the control cells (Fig. S1) . Collectively, these results are consistent with our hypothesis that mTOR pathway controls PHLPP expression by controlling the translation of PHLPP proteins.
The expression of PHLPP is regulated by amino acid availability in cells -It is evolutionarily conserved from yeast to human that the presence of amino acids strongly promotes the activation of mTOR (22) . This regulation is critical in balancing protein production based on the nutrient availability. To examine whether PHLPP expression is regulated by amino acids via the mTOR pathway, we determined the change of PHLPP levels in cells deprived of amino acids. In all cell lines tested, amino acid starvation for 50 minutes resulted in a ~30-70% reduction in PHLPP expression. Feeding cells with amino acids restored the expression of both PHLPP isoforms (Fig. 6A) . This amino acid-dependent regulation of PHLPP expression was observed in normal lung epithelial BEAS-2B cells as well (Fig. 6B) . Dephosphorylation of p70S6K at T389 site after amino acid starvation and increased phosphorylation after amino acid stimulation was used to show the change in mTOR activity ( Fig.  6A and 6B) . Furthermore, mTOR-mediated protein translation is known to be controlled by cellular glucose levels (23) (24) (25) . We examined the expression of PHLPP in cells grown in high (25 mM) or low (5 mM) glucose medium. As shown in Fig. 6C , low glucose condition led to 40-70% reduction of PHLPP levels consistent with inactivation of mTOR as indicated by decreased phosphorylation of p70S6K. Note that the phosphorylation of Akt was inversely correlated with the p70S6K activity in KM20 and SW480 cells indicating that Akt was controlled by the negative feedback regulation in these cells. However, the phosphorylation of Akt in 293T cells was usually unaffected by amino acid or glucose starvation. This is likely due to the expression of SV40 T-antigen in these cells. Taken together, our results demonstrate that the protein expression of PHLPP is regulated by physiological stimuli such as amino acid and glucose via an mTORdependent nutrient sensing mechanism.
Rapamycin-induced inhibition of PHLPP expression contributes to rapamycin resistance in colon cancer cells -Recent studies have indicated that certain cancer cell lines are resistant to rapamycin-mediated growth inhibition (26) (27) (28) . It has been suggested that rapamycin-induced disassembly of TORC2 complex and subsequent Akt dephosphorylation are required to achieve the sensitivity (26, 27) . Since PHLPP directly controls Akt phosphorylation, we postulated that inhibition of PHLPP translation in rapamycin-treated cells plays a role in the induction of drug resistance in cancer cells. Two colon cancer cell lines, SW480 and KM20, were used here to test whether overexpression of PHLPP enhances the growth inhibitory effect of rapamycin. Stable SW480 control (Con), PHLPP1 (P1), and PHLPP2 (P2) cells were treated with increasing concentrations of rapamycin, and the phosphorylation of Akt and cell proliferation were analyzed accordingly. In cells overexpressing PHLPP1 or PHLPP2, phosphorylation of Akt was largely decreased basally consistent with our previous findings in other cancer cell lines (12) (13) (14) (Fig. 7A ). Treating cells with rapamycin resulted in an increase of Akt phosphorylation in SW480 control cells likely due to the release of p70S6K-mediated negative regulation of PI3K (Fig. 7A, lanes 1-3) . In contrast, the phosphorylation of Akt remained low in PHLPP1 and PHLPP2 stable cells, while the exogenous expression of PHLPP remained high (Fig. 7A, lanes 4-9) . Consistent with previous findings, the control SW480 cells were relatively resistant to rapamycin-induced growth inhibition (10) . The rate of proliferation only reduced by ~20% with 20 nM rapamycin while Akt phosphorylation was not decreased (Fig. 7A and  7B ). Overexpression of PHLPP proteins significantly enhanced the growth inhibitory effect of rapamycin and resulted in a ~40% reduction in cell numbers in the presence of rapamycin (Fig.  7B) . Similarly, overexpression of PHLPP1 or PHLPP2 in KM20 cells decreased Akt phosphorylation basally (Fig. 7C, lanes 1-3) . Although KM20 cells were more sensitive to rapamycin treatment as indicated by loss of Akt phosphorylation (Fig.  7C , lanes 4-6), overexpression of PHLPP further reduced the rate of cell proliferation in rapamycin treated cells (Fig. 7D , ~30% inhibition in control cells vs. 60-70% inhibition in PHLPP overexpressing cells). Therefore, maintaining the level of PHLPP expression is critical in achieving more effective growth inhibition mediated by rapamycin. Moreover, overexpression of PHLPP proteins improves the efficacy of rapamycin in treating colon cancer cells suggesting that decreased PHLPP expression is likely a common mechanism underlying poor response to rapamycin in other cancer cells.
In summary, our results demonstrate that the expression of PHLPP is controlled by mTOR downstream of growth factor, amino acid, or glucose-mediated activation ( Figure 7E ). Two effectors of mTOR, p70S6K and 4E-BP1, are involved in regulating the translation of PHLPP proteins. In addition, since Akt positively regulates the expression of PHLPP via mTOR, an increase in PHLPP levels upon Akt activation functions in a negative feedback fashion to prevent hyperactivation of Akt signaling.
DISCUSSION
Hyperactivation of PI3K/Akt/mTOR signaling is commonly associated with increased tumorigenicity and resistance to chemotherapeutic drugs (3, 6) . The link between Akt and mTOR has been under intense investigation in recent studies as the possibility of targeting mTOR to antagonize PI3K/Akt signaling emerges in cancer therapy (29) (30) (31) . In this study, we investigated the mechanism by which the expression of PHLPP, a novel family of protein phosphatases, is regulated by the mTOR pathway. Our results show that the protein levels of both PHLPP1 and PHLPP2 are regulated by mTOR activity. While inhibition of mTOR by rapamycin or by knockdown of mTOR decreases PHLPP expression, depletion of TSC2, a negative regulator of mTOR, results in an increase in PHLPP expression. In addition, knockdown of 4E-BP1, a downstream effecter of mTOR and a negative regulator of protein translation, increases PHLPP expression and renders PHLPP resistant to rapamycin treatment. A similar effect is observed when a rapamycin-insensitive p70S6K mutant is expressed in cells. Furthermore, we show that the level of PHLPP expression may determine the rapamycin sensitivity in colon cancer cells. Taken together, our findings demonstrate a key role for mTOR in regulating the protein expression of PHLPP, a negative regulator of the Akt/mTOR pathway.
Regulation of PHLPP expression through mTORdependent protein translation
PHLPP represents a novel family of protein phosphatases that play an important role in antagonizing Akt signaling and suppressing tumor growth (12) (13) (14) . However, little is known about the regulation of PHLPP expression. In this study, we demonstrate that the level of both PHLPP isoforms is tightly controlled by mTOR activity in cells. There are several lines of evidence indicating that mTOR regulates the protein translation of PHLPP: (i) inhibition of mTOR activity either pharmacologically by using rapamycin and Torin1 or genetically by knocking down mTOR significantly reduces PHLPP expression; (ii) rapamycin-induced downregulation of PHLPP expression can be rescued by modulating two known regulators of protein translation downstream of mTOR, overexpression of a constitutively active p70S6K or knockdown of 4E-BP1; (iii) the mRNA level and the degradation rate of PHLPP proteins are not altered by rapamycin treatment or by knocking down TSC2; and (iv) PHLPP expression is readily regulated by physiological stimuli such as amino acid and glucose, which are well characterized regulators of mTOR-dependent protein translation. The differences in the change of PHLPP expression observed in our experiments are likely due to how sensitive the mTOR pathway is to various modulators in different cell lines. Curiously, although knockdown of rictor results in a large decrease of Akt phosphorylation (Fig. 1B) , and Akt is a known upstream activator of mTOR, the effect of decreased rictor expression on the level of PHLPP is relatively small. This can be explained by previous studies showing that rictor expression is only required for Akt signaling to FOXO3 but not to TSC2 or GSK3β (32) . In addition, knockout of protein components in the TORC2 complex, including rictor, mLST8, and Sin1, had very little effect on S6K activation (32, 33) . Thus, alteration of rictor expression is unlikely to affect TOCR1-dependent protein translation significantly. Consistent with this notion, it has been shown recently that skeletal muscle-specific deletion of raptor but not rictor results in metabolic changes leading to muscle dystrophy in mice (34) . In this study, we also find that knockdown of raptor and mTOR has considerably larger effect on PHLPP expression compared to knockdown of rictor. Taken together, we identify mTOR as a novel regulator of PHLPP expression via a translational mechanism.
mTOR-mediated regulation of PHLPP expression provides regulation of PI3K/Akt signaling via negative feedback
Due to its ability to sense signaling input from growth factor, nutrient, and energy, numerous studies have identified mTOR as a central regulator of protein translation (9) . The importance of keeping the balance in the mTOR pathway is exemplified by the involvement of mTOR in tumor promoting pathways leading to cancer (6) . Specifically, mTOR has been indicated as the major downstream effecter of the hyperactivated PI3K/Akt pathway in tumorigenesis (5, 35) . To prevent aberrant activation of the PI3K/Akt/mTOR axis under normal conditions, it is known that PI3K activity is modulated by a negative feedback loop involving mTOR-mediated activation of p70S6K and subsequent downregulation of IRS proteins (36, 37) . Our previous studies have shown that both PHLPP isoforms serve as negative regulators of Akt activity by directly dephosphorylating the kinase (12, 13) . In addition, we recently found that the activity of Akt dictates the rate of PHLPP degradation by controlling the extent of PHLPP ubiquitination (38) . These findings support a builtin feedback regulation in the PI3K/Akt pathway in which Akt activity can be self-regulated by controlling the expression of its phosphatase, PHLPP (38) . In this study, we have identified another feedback control involving mTORdependent regulation of PHLPP expression. In quiescent cells, the protein expression of PHLPP is likely kept low due to low level of mTOR activation. Upon stimulation by mitogens or nutrients, the expression of PHLPP increases as the result of mTOR-dependent activation of protein translation. This increase of PHLPP expression sets a higher activation threshold for Akt, thus, preventing Akt hyperactivation.
Role of maintaining PHLPP expression in cancer treatment
The importance of maintaining phosphatase activity in combating cancer drug resistance has been implicated by a recent study in which upregulation of Akt activity has been linked to resistance to tyrosine kinase inhibitor therapy in breast cancer cells (39) . Loss of phosphatase activity in addition to upregulation of HER3 has been indicated as the underlying mechanism for the increase of Akt activation and subsequent drug resistance (39) . Similarly, several studies have suggested that sustained phosphorylation of Akt contributes to rapamycin resistance in cancer cells (26) (27) (28) . Recent developments of dual-specific inhibitors of PI3K and mTOR and a newer generation of ATP-competitive kinase inhibitors of mTOR provide an attractive strategy to target rapamycin resistant tumors (31, 40) . Here, we show that loss of PHLPP expression induced by rapamycin is likely another contributing factor to rapamycin resistance in cancer cells. It is of particular interest to determine whether downregulation of PHLPP expression is involved in other instances of drug resistance in future studies. Indeed, a recent study indicates that decrease of PHLPP expression is found to be associated with chronic myelogenous leukemia (CML) cells with activated Bcr-Abl, and further depletion of PHLPP in CML cells using RNAi renders the cells resistant to Abl kinase inhibitors (41) . Therefore, enhancing PHLPP function may present a novel strategy to increase the effectiveness of cancer treatment. 293T (lanes 1-3) , MB-MDA231 (lanes 4-6), KM20 (lanes 7-9), and SW480 (lanes 10-12) cells were treated with rapamycin (20 nM) for 0-8 hours. The expression levels of PHLPP1 and PHLPP2 were detected by the PHLPP1 and PHLPP2 antibodies, respectively. Tubulin was used as the loading control throughout this study. (B) The expression of both PHLPP isoforms is decreased in mTOR and Raptor knockdown cells. Stable control (Sh-Con), mTOR (ShmTOR), raptor (Sh-Raptor), or rictor (Sh-Rictor) knockdown cells, including KM20 (lanes 1-4) and SW480 (lanes 5-8), were analyzed for PHLPP expression using PHLPP-specific antibodies. The expression of mTOR, raptor, and rictor was detected using the mTOR, raptor, and rictor antibodies, respectively. The phosphorylation status of Akt at T308 and S473, p70S6K at T389, and S6 at S240/S244 was detected using the phospho-T308 (p308), phospho-S473 (p473), phospho-T389 (p389), and phospho-S6 (pS6) antibodies, respectively. (C) Western blots of PHLPP1 and PHLPP2 as shown in (B) were quantified using the FluoChem digital imaging system. The relative expression of PHLPP was obtained by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin, and the quantitative results were expressed graphically. Data shown in the graph represent the mean ± SEM (n=4). 2) and SW480 (lanes 3 and 4), were analyzed for PHLPP expression using the PHLPP-specific antibodies. The expression of TSC2 was detected using the anti-TSC2 antibody. The phosphorylation of p70S6K at T389, S6 at S240/S244, and Akt at S473 was detected using the p389, pS6, and p473 antibodies, respectively. (B) The relative expression of PHLPP isoforms was quantified by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin, and this number for the control cells was set to 1. The level of PHLPP expression in TSC2 knockdown cells was normalized to the control cells and expressed graphically. Data shown in the graph represent the mean ± SEM (n=3). The relative expression of both PHLPP isoforms was obtained as described in (B), and the numbers are indicated below the PHLPP panels. The phosphorylation status of Akt at S473 and p70S6K at T389 was detected using the phospho-specific antibodies for these two sites. 2) and KM20 (lanes 3 and 4) were analyzed for PHLPP expression using the PHLPP-specific antibodies. The numbers shown below the PHLPP1 and PHLPP2 panels represent the relative expression of each PHLPP isoform in these cells. The expression of p70S6K and the phosphorylation status of its substrate, S6, were detected using the p70S6K and pS6 antibodies. (B) The relative expression of PHLPP isoforms was quantified by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin, and this number for the control cells was set to 1. The level of PHLPP expression in p70S6K knockdown cells was normalized to the control cells and expressed graphically. Data shown in the graph represent the mean ± SEM (n=3). (C) Overexpression of a rapamycin-resistant mutant p70S6K prevents PHLPP downregulation in rapamycin treated cells. 293T cells transfected with vector (lanes 1-6) or HA-p70S6K/T389E (lanes 7-12) were treated with rapamycin for 0-24 hours. The expression of both PHLPP isoforms was detected using the PHLPP-specific antibodies. The endogenous and overexpressed p70S6K and the phosphorylation and total protein expression of S6 were detected using the p70S6K, pS6, and S6 antibodies, respectively. (D) Western blots of PHLPP1 and PHLPP2 as shown in (B) were quantified using the FluoChem digital imaging system. The amount of PHLPP remained was obtained by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin, and the quantitative results were expressed graphically. Data shown in the graph represent the mean ± SEM (n=3). 2) and MB-MDA-231 (lanes 3 and 4), were analyzed for PHLPP expression using the PHLPP-specific antibodies. The expression of 4E-BP1 and the phosphorylation of Akt at S473 were detected using the 4E-BP1 and p473 antibodies, respectively. The relative phosphorylation level of Akt was obtained by normalizing ECL signals generated by p473 to that of tubulin, and the numbers are indicated below the p473 panel. (B) Western blots of PHLPP1 and PHLPP2 as shown in (A) were quantified using the FluoChem digital imaging system. The relative expression of PHLPP was obtained by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin and expressed graphically. Data shown in the graph represent the mean ± SEM (n=3). (C) PHLPP isoforms are resistant to rapamycin-or Torin1-induced downregulation in 4E-BP1 knockdown MB-MDA-231 cells. The control and 4E-BP1 knockdown cells were treated with rapamycin (20 nM) or Torin1 (100 nM) for 0, 4, and 12 hours. The total cell lysates were analyzed for PHLPP expression. The expression of 4E-BP1 and the phosphorylation of p70S6K at T389 were detected using the 4E-BP1 and p389 antibodies, respectively. (D) Quantitative representations of blots shown in (C). The relative expression of PHLPP isoforms was quantified by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin, and this number for the control cells was set at 100%. The decay rates of PHLPP isoforms remain similar in TSC2 knockdown cells. Stable KM20 control (Sh-Con, lanes 1-6) and TSC2 knockdown (Sh-TSC2, lanes 7-12) cells were treated with CHX and chased for 0-24 hours. The total cell lysates were analyzed for PHLPP1 and PHLPP2 expression. (B) Western blots as shown in (A) were was quantified, and the amount of PHLPP isoforms remained was obtained by normalizing ECL signals generated by the PHLPP1 antibody to that of tubulin, and the quantitative results were expressed graphically. Data shown in the graph represent mean ± SEM (n=3). (C) Rapamycin treatment has no effect on PHLPP degradation. 293T cells were treated with CHX along (lanes 1-6) or in combination with rapamycin (lanes 7-12) and chased for 0-24 hours. The expression of PHLPP was analyzed in the cell lysates using the PHLPP-specific antibodies. (D) Western blots as shown in (C) were analyzed as described above. Data shown in the graph represent the mean ± SEM (n=3). 3) , KM20 (lanes 4-6), and SW480 (lanes 7-9) were grown in regular growth medium containing serum (S), and subsequently switched to amino acid-free media for 1 hour (-) followed by stimulation with 1X amino acid containing media (AA) without serum for 2 hours. (B) The normal human lung epithelial BEAS-2B cells were treated and analyzed as described in (A). (C) 293T (lanes 1 and 2) and SW480 (lanes 3 and 4) cells were grown in regular growth medium until reaching ~70% confluency. The cells were then switched to serum free medium containing high (H, 25 mM) or low (L, 5 mM) glucose and incubated for 24 hour. For Western blot analysis, the cell lysates were probed for PHLPP expression using PHLPP specific antibodies. The phosphorylation of p70S6K at T389 site was used to show the effect of amino acid on mTOR activity. The phosphorylation of Akt at T308 and S473 were detected using the p308 and p473 antibodies, respectively. The relative expression of PHLPP isoforms was quantified by normalizing ECL signals generated by the PHLPP antibodies to that of tubulin, and these numbers were shown below the corresponding blots. 1-3) , HA-PHLPP1 (P1, lanes 4-6), or HA-PHLPP2 (P2, lanes 7-9) were treated with increasing concentration of rapamycin (0, 10, and 20 nM) for 24 hours. The cell lysates were analyzed for PHLPP expression and Akt phosphorylation. Note that overexpressed PHLPP2 protein was detected by the PHLPP1 antibody in P2 cells (detection of PHLPP2 proteins in PHLPP1 blot, lanes 7-9). This antibody cross-reactivity is not observed with endogenous proteins. (B) Overexpression of PHLPP isoforms sensitizes SW480 cells to rapamycin-induced growth inhibition. Equal numbers of stable SW480 control, P1, and P2 cells were treated with 0, 10, or 20 nM of rapamycin in serum containing media, and allowed to grow for 72 hours. The cells were then fixed and stained with crystal violet, and the absorbance at 570 nm was measured. The absorbance obtained from cells grown in media without rapamycin was treated as the control point (i.e. 100% cell growth with no inhibition), and the percentage of cell growth was calculated by normalizing other OD measurements to the control point. Each experimental point was done in duplicates, and three independent experiments were averaged and shown in the graph (mean ± SEM). The asterisks in all graphs indicate p<0.05 as determined by two-sample t-tests compared to the control cells. (C) KM20 cells infected with control (lanes 1 and 4) , HA-PHLPP1 (lanes 2 and 5), or HA-PHLPP2 (lanes 3 and 6) retrovirus were treated with 20 nM rapamycin for 24 hours and analyzed for PHLPP expression and Akt phosphorylation. (D) KM20 cells infected with control or PHLPP virus were left untreated or treated with 20 nM rapamycin, and allowed to grow for 72 hours. The numbers of cells were counted and this number for the control cells without rapamycin was set at 100%. The percentage of cell growth was obtained by normalizing to the control cells accordingly. Each experimental point was done in duplicates, and the graph represents average of two independent experiments (mean ± SD). The asterisks in all graphs indicate p<0.05 as determined by two-sample t-tests to compare the results obtained in P1 and P2 cells to the control cells. (E) Diagram showing mTOR-mediated regulation of PHLPP protein expression. Our study here demonstrates that mTOR activity is required for PHLPP expression by controlling protein translation through p70S6K and 4E-BP-1. Upregulation of mTOR function by knocking down TSC2 increases PHLPP expression, while inhibition of mTOR pathway by amino acid starvation or knockdown of mTOR itself decreases PHLPP expression. In addition, overexpression of a constitutively active mutant p70S6K or knockdown of 4E-BP1 renders PHLPP resistant to rapamycin-induced downregulation. A negative feedback regulation is achieved in which activation of Akt is effectively controlled by upregulation of its negative regulator, PHLPP, via mTOR-dependent protein translation.
